As the newest anti-vascular endothelial grown factor (VEGF) drug,alfibercept binds to all forms of VEGF-A,VEGF-B, and PIGF.So far, intravitreal injection of alfibercept has already been used to treat certain opthalmological diseases, such as neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, central retinal vascular occlusion, diabetic macular edema, corneal neovascular,and retinopathy of prematurity.In this article,we contrasted alfibercept to the other anti-VEGF drugs, conducted a review of the recent research progress of alfibercept in opthalmological diseases and introduced the questions which still need to be solved and the probably research direction of alfibercept in the future.%Alfibercept是一种新型抗血管内皮生长因子(VEGF)药物,它能与VEGF-A和VEGF-B的所有亚型以及胎盘生长因子(PIGF)相结合.目前Alfibercept已被玻璃体腔注药治疗一些眼科疾病,如新生血管性年龄相关性黄斑变性(NAMD)、息肉状脉络膜血管病变(PCV)、视网膜中央静脉阻塞(CRVO)、糖尿病黄斑水肿(DME)、角膜新生血管及早产儿视网膜病变(ROP)等.本文将Alfibercept和其他抗VEGF药物比较,并就其在眼科疾病中的研究进展予以综述,最后提出了Alfibercept在眼科疾病的治疗中需要解决的问题和今后的研究方向.
展开▼